Dazzling photos show the July full 'buck moon' reach peak illumination
The name 'buck moon' is in reference to male deer, or bucks, which start to rapidly grow their antlers this time of year. This year's buck moon reached its peak illumination at 4:37 p.m. ET on Thursday, which is when it was fully visible and low on the horizon for stargazers in North America.
This full moon was so visibly low on the horizon because of the summer solstice, which kicks off the summer and marks when the sun starts traveling at its highest point in the day. When the sun is at its high peak, the moon travels along a lower path throughout the night, according to Space.com. Due to its low position in the sky, buck moons tend to look a little orange because of Rayleigh scattering, which is the same thick atmosphere that makes us see sunsets as very orange.
A full moon happens when the sun, Earth and moon are in alignment and form a straight line. Since the moon and the sun are on either side of Earth, the sun's light shines on the moon entirely, making it look fully illuminated from the Earth's perspective, according to the Farmers' Almanac.
Even if you missed the buck moon on July 10, the full moon will still be clearly visible over the next few nights, according to Space.com. There are only five full moons left in 2025, the next one being the 'sturgeon moon' on Aug. 9, and three supermoons in October, November and December, according to a schedule by the Farmers' Almanac.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals
Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies BOULDER, Colo., Aug. 20, 2025 /PRNewswire/ -- KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C funding round, raising a total of $8 million and surpassing its targeted capital goals. The most recent tranche of the round contributed $3.8 million. The round was led by BroadOak Capital Partners, with participation from both existing and new strategic investors. The capital from this Series C close will fuel expansion of KROMATID's proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy. "We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology," said Jim Chomas, CEO of KROMATID. "This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients." "KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry," said Bill Snider, Partner at BroadOak Capital Partners. "We are proud to continue our partnership as they enter their next phase of growth." Over the next 12–18 months, KROMATID plans to deploy this funding to accelerate commercial expansion and enhance automation and throughput in its laboratory operations. The company will also invest in strategic hiring across scientific, operational, and customer-facing teams to meet increasing market demand and solidify its leadership position in genomic structural analysis. About KROMATIDKROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval. About BroadOak Capital PartnersBroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has invested in more than 70 life sciences companies including over 35 exits. For more information, visit Media Contact:Amanda LadasGlobal Marketing ManagerKROMATIDaladas@ View original content to download multimedia: SOURCE KROMATID Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Bio-inspired seashell design turns recycled plastics into consistent, strong materials
Georgia Tech researchers have developed a seashell-inspired material that could transform how recycled plastics are used, making them stronger, more consistent, and cheaper to produce. The breakthrough, led by aerospace engineering assistant professor Christos Athanasiou, could slash the cost of virgin packaging materials by nearly 50 percent and keep more waste out of landfills. The work addresses inconsistency, one of recycling's biggest problems. Less than 10 percent of the 350 million tons of plastic produced each year is effectively recycled, and when it is, the resulting material often can't be trusted for high-performance applications. Nature's blueprint for strength In typical mechanical recycling, plastics are melted together into an unpredictable mix. This randomness creates weaker, less reliable material, unsuitable for critical uses like car components or construction parts. Seashells, however, thrive on imperfection. Their structure, called nacre, is made of brittle mineral 'bricks' bonded with soft protein 'mortar.' This architecture dissipates energy and prevents catastrophic failure, creating robustness without purity. Athanasiou's team borrowed this natural strategy for their synthetic composite design. From pallet wrap to performance The team used recycled high-density polyethylene (HDPE), the clear stretch film that wraps pallet loads, and cut it into sheets. These 'bricks' were layered with a softer adhesive polymer 'mortar' to mimic nacre's architecture. When tested on a custom mechanical setup, the bio-inspired material maintained the original performance of virgin plastic while reducing variability in a key performance measure — maximum elongation — by more than 68%. The researchers also developed an 'uncertainty-aware' Tension Shear Chain model to quantify not just strength, but the reliability of performance. HDPE stretch film usually can't be reused for its original purpose after recycling because exposure to sunlight, heat, and stress changes its molecular structure. Athanasiou likens it to 'reusing a parachute without checking for rips.' The seashell-inspired approach, however, restores the material's trustworthiness, opening the door to high-performance reuse. Although the study focuses on plastics, the aerospace connection is clear. Space systems require materials that stay reliable in extreme environments. The same principles could one day help NASA's Lunar Recycling Challenge, where waste materials might be repurposed into survival infrastructure. Next, the team plans to expand the approach to other plastics, pair it with greener adhesives, and explore its potential for off-Earth construction, proving that what nature perfected in the ocean could help solve waste problems on Earth and beyond. Although the study focuses on plastics, the aerospace connection is clear. 'Whether it's a reusable rocket part or a shelter on Mars, we need materials that are resilient across their entire lifecycle,' Athanasiou said. 'Our study tackles a fundamental mechanics problem: how do you build reliable structures from unreliable materials?' The team is now scaling the approach to other recycled plastics and experimenting with bio-based adhesives for greater sustainability. 'Nature doesn't purify — it organizes,' Athanasiou added. 'We're taking that philosophy and applying it to a problem that affects both Earth and the future of space exploration.' The findings of the study have been published in the journal Proceedings of the National Academy of Sciences. Solve the daily Crossword
Yahoo
41 minutes ago
- Yahoo
iSpecimen's $6M Valuation Doesn't Reflect the Business-Let Alone the $200M Treasury (NASDAQ: ISPC)
WOBURN, MA / / August 20, 2025 / A share price of $1.11. A $6.1 million market cap. Just 5.54 million shares outstanding. And a newly announced $200 million digital treasury. On paper, the disconnect between price and intrinsic value, let alone inherent potential, is hard to miss. But the real takeaway isn't just the contrast. It's what that contrast says about iSpecimen Inc. (NASDAQ:ISPC): a company with a functioning platform, measurable revenue, and real-world utility that remains miscategorized and underpriced by the market.(ISPC Share count and price data on 8/20/2025) The digital treasury announcement deserved headlines. It's rare for any microcap, especially in life sciences, to unveil a capital strategy of that scale. But the attention came with a surprising market reaction. Following the news, ISPC shares moved lower. That drop wasn't tied to any breakdown in the business. It was likely due to timing. The news hit after-hours, when retail investors had little access and institutions hadn't yet responded. What the market saw was the number. What it didn't see was the system behind it. Solving the Bottleneck in Life Sciences iSpecimen is not a clinical-stage biotech, nor is it speculative software. It operates a fully functional digital marketplace for human biospecimens-vital inputs for both preclinical and clinical research. The platform allows researchers to efficiently source high-quality, well-characterized specimens with full traceability and regulatory compliance. Blood, plasma, tissue, and genomically sequenced material are the raw materials of discovery, yet sourcing them has long been a fragmented, manual, and inefficient process. iSpecimen fixes that. Its proprietary, cloud-based platform lets researchers search, filter, and request exactly what they need based on disease state, demographic, clinical history, or processing requirements. On the other end, hospitals and labs can monetize excess inventory. iSpecimen handles compliance, logistics, and invoicing. The result is a streamlined transaction that unlocks value for both sides. This isn't a roadmap or beta test. The platform is live, and it's producing revenue. In 2024, the company posted $9.29 million in revenue. That number didn't come from grants or one-time licensing. It came from platform activity, repeated use, and institutional adoption. The Treasury is Not a Gimmick - It's a Strategic Asset The $200 million digital treasury that sparked attention isn't accounted for as cash on the balance sheet. But that doesn't mean it lacks financial weight. It is a capital preservation and liquidity strategy built to support long-term operations. Built on Solana, it features insured custody, cold storage, and a risk-managed structure that removes reliance on traditional capital markets. This isn't a distraction. It's financial insulation. It allows iSpecimen to grow without falling into the trap of repeated, dilutive financing. That kind of flexibility, especially for a microcap, is rare. But while the market focused on that headline, it missed the infrastructure behind it. iSpecimen's core business is still the real story. Expanding Reach Across Critical Therapeutic Areas Behind the scenes, the company is scaling its footprint across several high-value segments of medicine. In cancer research, it's now working with U.S.-based oncology centers and a genomic sequencing partner to deliver hard-to-source biospecimens for precision studies. In women's health, iSpecimen has access to over 600,000 patients through multi-state partnerships, unlocking samples across reproductive, hormone, and breast health. And in early 2025, the company proactively secured sourcing for human metapneumovirus (hMPV), anticipating potential waves of global research interest. Each of these initiatives adds operational depth to a platform that was already delivering. None of it would matter if the core system didn't work. But it does, and the results are increasingly visible. When the Market Doesn't Know Where to Look The mispricing here may stem from the fact that iSpecimen doesn't fit cleanly into a familiar category. It's not chasing regulatory approval, so it doesn't trade on FDA calendars. It's not a SaaS company, though its platform behaves like one. Instead, it sits between logistics, life sciences, and digital infrastructure - and that ambiguity often delays recognition. But that's also where value hides. iSpecimen runs an asset-light, transaction-based model. It doesn't need to build labs or develop its own trial pipeline. It monetizes what already exists by organizing and standardizing the connections between researchers and providers. That model is scalable across disease areas, institutions, and even global geographies. This Isn't a Bet. It's a Repricing in Progress The treasury may have been the headline, but it isn't the whole story. It's simply a structural advantage layered onto a business that is already performing. The marketplace, the revenue, the partnerships, and the platform all existed before the $200 million plan was announced. Thus, ISPC isn't a company hoping for validation. It's a company that already has it - just not from the market yet. At $1.11, the share price reflects none of that. But that doesn't mean the value isn't there. It just means the recognition hasn't arrived yet. When it does, the most temporary number in this entire story might be the one investors are staring at right now. *Reprinted with permission from Hawk Point Media Group, LLC. About iSpecimen iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact:Investor Contactsinfo@ For this content only: info@ Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated five thousand dollars to create this content as part of a more extensive digital marketing program by IR Agency, Inc. Accordingly, this content may be reused and syndicated beyond the channels used by Hawk Point Media, LLC. This disclaimer and the link to the broader disclosures must be part of all reproductions. That compensation creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in iSpecimen Inc. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment. SOURCE: iSpecimen, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
